申请人:DeVita J. Robert
公开号:US20050026915A1
公开(公告)日:2005-02-03
The present invention is concerned with compounds of the general Formula I:
and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
本发明涉及一般式I的化合物及其药学上可接受的盐,其作为黑色素浓集激素受体拮抗剂,特别是MCH-1R拮抗剂而有用。因此,本发明的化合物可用于治疗或预防与过度食物摄入及其并发症有关的肥胖症或进食障碍,骨关节炎,某些癌症,艾滋病消耗症,消瘦,衰弱(尤其是老年人),精神障碍,压力,认知障碍,性功能,生殖功能,肾功能,运动障碍,注意力缺陷障碍(ADD),物质滥用障碍和运动障碍,亨廷顿病,癫痫,记忆功能和脊髓肌萎缩。因此,式I的化合物可用于治疗这些疾病,并用于制造用于治疗这些疾病的药物。本发明还公开了包含式(I)中的一种化合物作为活性成分的制药配方,以及制备这些化合物的过程。